EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.04 | $899,000 | $2M |
| 2025 Q4 | 0.02 | $10M | $28,000 |
| 2025 Q3 | -0.01 | $5M | $336,000 |
| 2025 Q2 | -0.02 | $5M | -$3M |
| 2025 Q1 | 0.01 | $845,000 | $560,000 |
| 2024 Q4 | -0.03 | $7M | -$2M |
| 2024 Q3 | -0.02 | $4M | -$459,000 |
| 2024 Q2 | 0.02 | $4M | -$1M |